Flemming Ornskov

Cantillon: Shire takeover of Baxalta fails to impress shareholders

Shire shares slide 8% as analysts concerned about ambitious savings target from merger

Shire to buy Dyax for $5.9 bn

Deal will give Dublin-based pharma group access to treatment for inflammatory disease

Shire results beat forecasts as it still tracks Baxalta

CEO Flemming Ornskov refused to be drawn on whether drugmaker will pitch new higher offer

Shire seeks access to $30bn takeover target Baxalta’s books

Shire CEO confident Baxalta shareholders are open to a deal

Shire seen having to raise $30bn Baxalta bid

Investor says shareholders in Dublin company may back increase from current $45.23 a share offer to $50 but some unease over scale of acquisition

Shire beats analysts’ forecasts with first-quarter earnings

Dublin-based company wins more sales for drugs treating ADHD

Shire structure puts spotlight on tax

Drug firm has come out fighting after allegations it engaged in tax avoidance on an industrial scale

Dublin-headquartered Shire faces fresh scrutiny over tax

Questions on firm’s $1.6 billion “break fee” from AbbVie

Patent win helps Shire as AbbVie plots next bid move

London-listed pharma company has already spurned a $46 billion takover offer from US firm

Shire worth more than Abbvie bid, says CEO

Product sales will increase at a double-digit rate with expansion in drugs for rare diseases

Generic competition pushes Sanofi to 34% fall in first-quarter profit

Rival Shire misses estimates amid increased competition

Most Read

1

21-degree seawater, blue sky above: A glorious swim in Clontarf Baths, now open to all

2

Hilary Fannin: The seaside town I used to visit is almost unrecognisable

3

Plan to fast-track cuts to €3,000 student contribution fee

4

Diarmaid Ferriter: Greece burns while the tourists fiddle with their phones

5

Gardaí question man over fatal stabbing of woman in Co Meath

You may also like...

The Irish Times ePaper